hematology-2017-scientifictracks-abstracts

5 / 22

Page 24
Notes:
conferenceseries .com
Volume 8, Issue 5 (Suppl) J Blood Disord Transfus, an open access journal
ISSN:2155-9864 Hematology 2017
November 08-09, 2017
November 08-09, 2017 | Las Vegas, USA
11th International Conference on
Hematology & Hematological Oncology
Global incidence and prevalence of acute lymphoblastic leukemia: A 10-year forecast
Bethlehem Solomon, Narendra Parihar, Lade Ayodele and Michael Hughes
Decision Resources Group, USA
Acute Lymphoblastic Leukemia (ALL) incidence is increasing globally and the case burden is expected to rise among adults
in whom the disease is particularly fatal. The aim was to estimate changes in ALL risk and disease burden globally over
the next decade. Using data from country-specific cancer registries, incidence was estimated for 45 countries, representing
approximately 90% of the world population. Increasing age and male sex were the non-modifiable risk factors with the largest
effects. To account for additional risk factors such as the increasing adoption of Western lifestyles characterized by dietary
changes and more sedentary lifestyles, the proxy measure of forecast gross domestic product (GDP) were used. Prevalence
was also estimated as a cumulative incidence over the preceding 12-month period with adjustments for disease-specific and
competing-cause mortality. In 2020, we estimate ALL incidences to range from 0.4 to 2 per 100,000 in Asia-Pacific and South
American countries, respectively; while prevalence will range from 0.37 to 1.6 per 100,000 in these regions. In terms of case
burden, when accounting for the approximate 10%of the world’s population not covered by the 45 countries inwhichwe forecast
incident and prevalent cases, there were a total of 53,000 cases in 2016 worldwide. Incorporating the aforementioned risk
factors into a forecast model using demographic and GDP data published by the United Nations and World Bank, respectively,
this number should increase to 56,000 cases by 2020. Most of these cases are in the Asia Pacific region, representing 55% of the
worldwide total.
Biography
Bethlehem Solomon has completed her MPH, concentrating in both Epidemiology and Global Health from Boston University School of Public Health, USA. She is
an Associate Epidemiologist with a focus on Oncology at Decision Resources Group, USA. She was a Visiting Scientist at the University of Cambridge/Wellcome
Trust Sanger Institute, where she participated in the design and implementation of various studies focusing on non-communicable diseases, particularly in low and
middle-income countries.
Bethlehem Solomon et al., J Blood Disord Transfus 2017, 8:5 (Suppl)
DOI: 10.4172/2155-9864-C1-028